hLife最新文献

{"title":"Advancements for microbiome research in human health and disease: From composition to functionality","authors":"Nan Qin , Stanislav Dusko Ehrlich","doi":"10.1016/j.hlife.2024.08.002","DOIUrl":"10.1016/j.hlife.2024.08.002","url":null,"abstract":"","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 10","pages":"Pages 542-545"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142533680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kha-Ti Lim: Mother of ten thousand infants","authors":"","doi":"10.1016/j.hlife.2024.04.004","DOIUrl":"10.1016/j.hlife.2024.04.004","url":null,"abstract":"","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 10","pages":"Pages 493-495"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140787816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and investigation of all-in-one microneedles complexed with functionalized polydiacetylene liposomes for improved in situ detection sensitivity","authors":"Jiarui Wang ,&nbsp;Weimiao Li ,&nbsp;Yan Chen ,&nbsp;Meng Wu ,&nbsp;Yan Shi ,&nbsp;Jumin Lee ,&nbsp;Ming Kong","doi":"10.1016/j.hlife.2024.07.005","DOIUrl":"10.1016/j.hlife.2024.07.005","url":null,"abstract":"<div><div>Polydiacetylene (PDA) liposomes have been widely applied for detection due to their distinctive optical properties. However, the liquid phase in which PDA liposomes are dispersed generates several drawbacks, for instance, instability, compromise of detection sensitivity induced by dilution, and separation of target sampling and detection, making it inconvenient for application. In this paper, various functionalized PDA liposomes for detecting target were prepared, which were also immobilized into swelling microneedles to construct a solid-phase detection system. The PDA liposomes-complexed microneedles (PDA/MNs) enable the integration of target sampling and detection in one platform. The effects of the dispersing matrix phase on the detection sensitivity of PDA liposomes were systematically investigated from both environmental and chemical perspectives. PDA/MNs exhibited higher sensitivity than their counterparts in liquid phase. PDA/MNs were optimized and validated for lead ion (Pb²⁺) and sialic acid (SA) detections. For Pb²⁺ detection, the limit of detection (LOD) of the PDA/MNs was 13.7 μM and 2.5 times lower than the liquid phase. For SA detection, the LOD of the PDA/MNs was 0.83 μM and 1.7 times lower than the liquid phase. The results suggested that such PDA/MNs were validated to provide a label-free, stable, sensitive, and convenient tool in an all-in-one manner for physiologic target detection.</div></div>","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 10","pages":"Pages 514-526"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surpassing the natural limits of serological diagnostic tests","authors":"","doi":"10.1016/j.hlife.2024.06.001","DOIUrl":"10.1016/j.hlife.2024.06.001","url":null,"abstract":"<div><div>Serological tests have an important and irreplaceable role in the diagnosis of infectious diseases, both for individual patients and society. They indirectly identify the causative pathogen through the capture of antibodies, which contrasts with the direct detection by antigen and molecular biology tests that are also limited to active infections. Within point-of-care platforms, serodiagnostic assays can support immediate decisions in patient care and contain the spread of disease as they do not require highly trained personnel or dedicated infrastructure. By employing serodiagnosis, health officials can proactively respond and eliminate emerging health risks. Larger sample numbers can be screened in other formats for surveillance as well as securing donated blood supplies. Furthermore, an assay can be designed to detect any immunoglobulin from IgM to IgG and its subclasses, to IgA and IgE. However, most serological assays employ natural proteins as the defining antibody-capturing reagent, which compromises their performance by limiting the two critical parameters of a serodiagnostic test: specificity and sensitivity. To surpass this natural limitation, we have repurposed the β-barrel of fluorescent proteins to receive epitope sequences that dependably produce high-performing designer immunological reagents. Consequently, serodiagnosis can be conducted more accurately at a lower cost.</div></div>","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 9","pages":"Pages 467-470"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000476/pdfft?md5=482905bb00c9e9befc43de6b36a959fb&pid=1-s2.0-S2949928324000476-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141410133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discoidin domain receptor 1 as a potent therapeutic target in solid tumors","authors":"","doi":"10.1016/j.hlife.2024.01.003","DOIUrl":"10.1016/j.hlife.2024.01.003","url":null,"abstract":"<div><div>Despite significant discoveries in basic cancer research and improvements in treatment options and clinical outcomes, cancer remains a major public health concern worldwide. Today, the main focus of cancer research is the signaling pathways that are crucial for cell survival, cell proliferation, and cell migration. The aberrant expression of proteins involved in these signaling pathways often leads to abnormal cell growth, cell metastasis, and invasion of healthy tissues. One such protein is discoidin domain receptor 1 (DDR1) which belongs to the family of receptor tyrosine kinases (RTKs) and is activated upon collagen binding, as a result, downstream signaling pathways are stimulated which are responsible for cell survival, cell growth, adhesion, extracellular matrix remodeling, and cell migration. DDR1 is found to have abnormally elevated expression in various solid tumors, implying a critical role in cancer progression. Traditional cancer treatment involves the use of cytotoxic drugs, chemotherapy, radiotherapy, and surgery, which do not provide long-term survival and often result in cancer recurrence. Numerous small-molecule kinase inhibitors have been synthesized against RTKs including DDR1 and have been highly efficacious in tumor reduction. More recently, targeting the DDR1 extracellular domain (ECD) has garnered much attention from researchers, as inhibiting the DDR1-collagen binding has been attributed to maximizing the likelihood of the combined cytotoxic effect of both immune cells and targeted drugs. This review focuses on the structure, function, activation, and signaling partners of DDR1, its role in different solid tumors, and finally discusses about designing more DDR1 non-kinase inhibitors as promising therapeutic strategies against DDR1-driven tumors.</div></div>","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 9","pages":"Pages 454-466"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000051/pdfft?md5=bc82c56122dee5f47002d68a90172204&pid=1-s2.0-S2949928324000051-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139639594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy","authors":"Zhongyao Chen ,&nbsp;Qiang Gao ,&nbsp;Yukui Shang ,&nbsp;Behzad Nasiri Ahmadabadi ,&nbsp;Yawei Hu ,&nbsp;Wei Zhang ,&nbsp;Peng Liu","doi":"10.1016/j.hlife.2024.07.004","DOIUrl":"10.1016/j.hlife.2024.07.004","url":null,"abstract":"<div><div>Diffuse midline glioma (DMG), H3K27-altered, is lethal pediatric-type, high-grade, localized to the midline region of the central nervous system. Effective treatment guidelines are absent, and clinical trials are preferred for primary or recurrent DMG patients. Recently, epigenetic agent-based immunotherapy has exhibited promising therapeutic effects in the clinical setting. However, the underlying mechanisms remain a mystery. The rare DMG tumor samples from biopsy or resection largely impede basic research, by using patient-derived tumor cells which better recapitulate the parental tumor's heterogeneity compared to established cell lines. As an epigenetic reprogramming disease, DMG exhibits a global loss of H3K27 trimethylation (H3K27me3) and a gain of H3K27 acetylation (H3K27ac). Analysis of multiple epigenetic marks is fundamentally necessary. However, traditional techniques cannot allow ultra-low input and high-throughput. Herein we have developed a new method called high-throughput <em>in situ</em> tagged immunoprecipitation sequencing (HiTIP-seq), which uses an integrated superhydrophobic microwell array technology (InSMART). We were able to perform 100 parallel assays from as few as 100 cells per microwell on a single chip. We applied the technology to profile epigenetic alterations of three-dimensional (3D) cell cultures derived from DMG patients. Our HiTIP-seq integrated with RNA sequencing (RNA-seq) analysis revealed that the combination of epigenetic agents (panobinostat and tazemetostat), reprogrammed histone modifications and drove transcriptome changes. Among them, Wnt inhibitory factor 1 (<em>WIF1</em>) has a gain of H3K27ac and a loss of H3K27me3, which leads to the upregulated expression. Altogether, HiTIP-seq is a versatile method for high-throughput analysis of histone modifications, suitable for both DMG research and studying rare 3D models.</div></div>","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 9","pages":"Pages 471-487"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000622/pdfft?md5=1644a1fd4587672755b878818279935d&pid=1-s2.0-S2949928324000622-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141698860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion","authors":"","doi":"10.1016/j.hlife.2024.05.004","DOIUrl":"10.1016/j.hlife.2024.05.004","url":null,"abstract":"","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 9","pages":"Pages 488-491"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000439/pdfft?md5=824179bdb442aefbee259064f827f7ce&pid=1-s2.0-S2949928324000439-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in surgical management strategies for hepatocellular carcinoma","authors":"Zhen-Bin Ding ,&nbsp;Ying-Hong Shi ,&nbsp;Jia-Feng Chen ,&nbsp;Jia Fan ,&nbsp;Jian Zhou","doi":"10.1016/j.hlife.2024.06.007","DOIUrl":"10.1016/j.hlife.2024.06.007","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is a significant global health challenge, requiring innovative methods to improve patient survival. Due to different disease backgrounds, different HCC management guidelines have been developed, especially in the field of surgical treatment, with the aim of reducing the risk of incidence and enhancing the therapeutic effect. Focusing on the progress and challenges in the development of surgical management strategies for HCC in recent years, this article systematically elaborates on the research and clinical application of precision surgical treatment, including improvement of the surgical evaluation system, breakthroughs in surgical techniques, and updates in perioperative treatment concepts. In addition, clinical research on surgical treatment for HCC has received unprecedented attention. The conclusions of innovative clinical trials in surgery will provide important guidance for the development of practice guidelines and the selection of appropriate treatment strategies for HCC patients.</div></div>","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 9","pages":"Pages 439-453"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000567/pdfft?md5=a638143a9a99027f8cf5c158251033e9&pid=1-s2.0-S2949928324000567-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovering broader antiviral strategies: Role of interferon-induced transmembrane proteins in virus infection","authors":"Zi-Ying Jiang ,&nbsp;Chu Xie ,&nbsp;Pei-Huang Wu ,&nbsp;Zhi-Xuan Li ,&nbsp;Mu-Sheng Zeng ,&nbsp;Cong Sun","doi":"10.1016/j.hlife.2024.07.002","DOIUrl":"10.1016/j.hlife.2024.07.002","url":null,"abstract":"","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 8","pages":"Pages 377-379"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000609/pdfft?md5=7cc92e6f494cccd5ec3d3af92a0239bc&pid=1-s2.0-S2949928324000609-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141713148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","authors":"Wei Zhang ,&nbsp;Dan Liu ,&nbsp;Tao Zhang ,&nbsp;Jiang Cao ,&nbsp;Gang Wang ,&nbsp;Huizhong Li ,&nbsp;Su Zhou ,&nbsp;Ruixue Zhang ,&nbsp;Yuqiao Wang ,&nbsp;Jinyu Li ,&nbsp;Zixuan Zhang ,&nbsp;Hao Chen ,&nbsp;Yong Zhang ,&nbsp;Shenyang Zhang ,&nbsp;Jie Zu ,&nbsp;Xiaopeng Wang ,&nbsp;Chuanying Xu ,&nbsp;Manli Zhou ,&nbsp;Ming Shi ,&nbsp;Guiyun Cui ,&nbsp;Junnian Zheng","doi":"10.1016/j.hlife.2024.05.005","DOIUrl":"10.1016/j.hlife.2024.05.005","url":null,"abstract":"","PeriodicalId":100609,"journal":{"name":"hLife","volume":"2 8","pages":"Pages 434-438"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949928324000440/pdfft?md5=d9543aa1a74f9f57c9a9b70ace2f809c&pid=1-s2.0-S2949928324000440-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}